...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality
【24h】

Ezetimibe in Combination With a Statin Does Not Reduce All-Cause Mortality

机译：ezetimibe与他汀类药物组合不会减少所有原因的死亡率

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Although the ezetimibe-statin combination has been shown to reduce LDL cholesterol by 12% compared to a statin alone, its effect on hard clinical endpoints such as mortality is less certain. Prior trials evaluated this combination in highly select population groups, but impact on all- cause mortality in the general population has not been reported.?Methods: A total of 3,827 subjects who were prescribed either a statin (group 1) or the combination of statin with ezetimibe (group 2) between January 1st, 2005 and January 1st, 2008 were studied. Socio-demographic and clinical variables and mortality records were analyzed. Univariate and stepwise multivariate logistic regression analysis was performed to identify the impact of ezetimibe on all-cause mortality, controlling for patient characteristics, selected cardiovascular diseases and risk factors, and medications.?Results: Group 1 (n = 2,909), and group 2 (n = 918) were similar in regards to most demographic variables, 152 patients died from any cause during the study period. There was no difference in all cause mortality between the groups. Hypertension, higher HDL-C and omega-3 fatty acid use were associated with ezetimibe use in this cohort of patients and were considered as covariates in the analysis. Patients on the drug combination did not experience lower mortality after controlling for covariates and other significant risk factors.?Conclusions: No significant mortality benefit was found with the use of ezetimibe in combination with a statin over use of a statin alone. Omega-3 fatty acid use and higher HDL-C demonstrated a substantial survival benefit.doi: http://dx.doi.org/10.4021/jocmr1371w
机译：背景：虽然与单独的他汀类药物相比已经显示ezetimibe-sataTin组合将LDL胆固醇减少12％，但其对死亡率的硬临床终点的影响不太确定。先前的试验在高度选择的人群中评估了这种组合，但尚未报告一般人口中的所有原因死亡率的影响.?Methods：总共有3,827名受试者，被规定的他汀类药物（第1组）或他汀类药研究了2005年1月1日至2008年1月1日至1月1日之间的ezetimibe（第2组）。分析了社会人口统计学和临床​​变量和死亡记录。进行单变量和逐步多变量逻辑回归分析，以确定ezetimibe对所有原因死亡率的影响，控制患者特征，选择的心血管疾病和危险因素，以及药物：第1组（n = 2,909），第2组（n = 918）对于大多数人口统计变量相似，152名患者在研究期间死于任何原因。所有导致组之间的死亡率都没有差异。高血压，较高的HDL-C和OMEGA-3脂肪酸使用与这种患者队列中的ezetimibe使用有关，并且被认为是分析中的协变量。药物组合的患者在控制协变量和其他显着风险因素后没有经历较低的死亡率。结论：在使用ezetimibe与他汀类药物同时使用ezetimibe没有发现显着的死亡效益。 Omega-3脂肪酸使用和更高的HDL-C显示了大量的生存益处.DOI：http：//dx.doi.org/10.4021/jocmr1371w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号